Currently, pharmacotherapy of coronary heart disease, based on antianginal drugs directly improve coronary blood flow, antiplatelet, and lipid-lowering drugs, includes a new class of drugs - cardiocytoprotectors. Recent ischemic cardiomyocytes improve security in the ATP, by optimizing the energy metabolism by reducing the need for oxygen cardiomyocytes and has an antioxidant effect, protecting cellular structures and enzymes from oxidative stress accompanying hypoxia.
| UI | MeSH Term | Description | Entries |
|---|